Somewhat Favorable Press Coverage Somewhat Unlikely to Impact CTI BioPharma Corp. (CTIC) Share Price
Press coverage about CTI BioPharma Corp. (NASDAQ:CTIC) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CTI BioPharma Corp. earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.18546187302 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Keeping Track of Indicators For CTi Biopharma Corp (CTIC) – Bulletin News (orobulletin.com)
- Unusual Activity Spotted in CTi Biopharma Corp (CTIC) – Sparta Review (spartareview.com)
- CTI BioPharma Corp. (CTIC)- Stocks Defying Gravity – NASDAQ Times (nasdaqtimes.com)
- Chartists Placing CTi Biopharma Corp (CTIC) on Their Radar – Stock Press Daily (stockpressdaily.com)
CTI BioPharma Corp. (NASDAQ:CTIC) traded up 2.12% during midday trading on Friday, hitting $3.37. The stock had a trading volume of 33,656 shares. The stock’s 50-day moving average is $3.39 and its 200-day moving average is $3.89. The company’s market cap is $106.91 million. CTI BioPharma Corp. has a one year low of $0.36 and a one year high of $6.48.
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.63. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%. The business had revenue of $22.23 million during the quarter. Equities analysts predict that CTI BioPharma Corp. will post ($2.40) EPS for the current fiscal year.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact CTI BioPharma Corp. (CTIC) Share Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/26/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-cti-biopharma-corp-ctic-share-price.html.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.